|Bid||18.38 x 0|
|Ask||19.32 x 0|
|Day's range||18.62 - 18.92|
|52-week range||14.81 - 37.29|
|Beta (5Y monthly)||0.96|
|PE ratio (TTM)||471.25|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces agreement with Janssen to develop immune-based therapies 26.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT Hamburg, Germany, 26 January 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a str
To get a sense of who is truly in control of Evotec SE ( ETR:EVT ), it is important to understand the ownership...
Last week saw the newest quarterly earnings release from Evotec SE ( ETR:EVT ), an important milestone in the company's...